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Abstract
With their article, Grutters et al raise an important question: What do successful health technology assessments 
(HTAs) look like, and what is their real-world utility in decision-making? While many HTAs are published 
in peer-reviewed journals, many are considered proprietary and their attributes remain confidential, limiting 
researchers’ ability to answer these questions. Models for economic evaluations like cost-effectiveness analyses 
(CEAs) synthesize a wide range of evidence, are often statistically and mathematically sophisticated, and 
require untestable assumptions. As such, there is nearly universal agreement among researchers that enhancing 
transparency is an important issue in health economic modeling. However, the definition of transparency and 
guidelines for its implementation vary. Model registration combined with a linked database of model-based 
economic evaluations has been proposed as a solution, whereby registered models and their accompanying 
technical and nontechnical documentation are sourced into a single publicly-available repository, ideally in a 
standardized format to ensure consistent and complete representation of features, code, data sources, results, 
validation exercises, and policy recommendations. When such a repository is ultimately created, modelers will 
not have to reinvent the wheel for every new drug launched or new treatment pathway.  These more open and 
transparent approaches will have substantial implications for model accuracy, reliability, and validity, improving 
trust and acceptance by healthcare decision-makers.  
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In seeking to understand the returns to early health economic modeling, Grutters et al1 found that assessments performed in early development led to 
further development and research, and that none resulted in 
a firm ‘no-go’ recommendation. These results suggest that 
the benefits of early modeling are potentially very high. With 
their article, Grutters et al raise an important question: What 
do successful health technology assessments (HTAs) look 
like, and what is their real-world utility in decision-making? 
As stated by Mandelblatt et al, “Models are only as good as 
their ability to represent reality at the level needed to draw 
useful conclusions; this, in turn depends upon their structure 
and on the assumptions that go in to the models.”2 The 
process of determining how ‘good’ a model is involves model 
validation (predictive and structural) and peer review.3 While 
there are tools for measuring the general quality of published 
economic models (eg, the Quality of Health Economic Studies 
instrument),4 there are no such standard tools for point-by-
point evaluation of validity and applicability in peer review. 
How, then, can we characterize the systematic factors of HTA 
success and failure?
One could begin by comparing models and their predictions 
against available data on market and health outcomes. 
However, this requires access to detailed information on 
models. While many HTAs such as cost-effectiveness 
analyses (CEAs) are published in peer-reviewed journals, 
many are considered proprietary and their attributes remain 
confidential. Due to confidentiality concerns, Grutters et al 
were limited in what they could report; only two assessments 
reviewed were published in scientific journals. As a result, they 
were unable to identify specific characteristics contributing to 
decisions favoring further model development or assess the 
key points of success and failure. 
The trade-offs between confidentiality and model 
transparency in CEA have been discussed in the literature 
for over a decade. Because CEAs synthesize a wide range 
of evidence, are often statistically and mathematically 
sophisticated, and require untestable assumptions, many 
key decision-makers may view models as proprietary black 
boxes designed to give biased results.5 In the United States, 
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for example, model results are often discounted by skeptical 
clinicians and policy-makers.6 While there is nearly universal 
agreement among researchers that enhancing transparency 
is an important issue in health economic modeling,7-9 
the definition of transparency and guidelines for its 
implementation vary, especially with respect to sharing model 
code.10 The Second Panel on Cost-effectiveness in Health 
and Medicine recommends that modelers should provide 
enough detail about model structure and parameterization 
to allow reproducibility, from making entire models available 
to providing versions that allow users to vary selected inputs, 
but makes no formal recommendation for sharing model 
code.7 The International Society for Pharmacoeconomics 
and Outcomes Research (ISPOR) and the Society of Medical 
Decision Making recommends that transparent models 
should provide enough information to enable readers, 
specialists and non-specialists alike, to understand a model’s 
accuracy, limitations, and potential applications.8 This 
requires non-technical documentation detailing model 
structure and potential applications, though not at the level 
of detail necessary for replication, in addition to technical 
documentation more substantially detailing model structure, 
equations, data input and, at the modeler’s discretion, access 
to model code to permit replication. 
While some argue that open-source publication of 
models would compromise intellectual property rights 
and disincentivize their development,11 economic models 
themselves often have minimal proprietary value, and in many 
situations, publication in a prestigious peer-reviewed journal 
is worth more than the ability to sell the model privately.6,12 
Several top scientific journals such as Nature, Cell, and 
Science now require data and/or code sharing with readers 
upon publication.13 Since most applied modeling techniques 
and software packages are standard among researchers in 
the field, model scripts and code contain little innovative 
intellectual property.12 Healthcare organizations are more 
likely to be concerned with the release of proprietary data 
from clinical trials. However, when clinical trials are biased or 
not adequately generalizable, those CEAs that use their results 
will suffer from these same limitations. 
Take, for example, a CEA comparing various strategies 
to reduce cholesterol involving diet, niacin, and lovastatin, 
published in Appendix C of Cost Effectiveness in Health and 
Medicine by Gold et al,14 a landmark instructional book for 
economic modeling in healthcare. At the time of the book’s 
publication in 1996, clinical trials on niacin showed favorable 
changes in lipid profiles.15-18 Although it had not been 
established in clinical research that niacin’s effect on lipid levels 
resulted in lower rates of cardiovascular events, the authors 
assumed that such a relationship existed between lipid levels 
and cardiovascular risk for niacin users. Using the biomarker 
results, the authors of the CEA concluded that care with niacin 
was cost-effective for prevention of cardiovascular disease, 
and in 1997, the US Food and Drug Administration approved 
a prescription extended-release version of niacin. However, 
nearly two decades later, the results of two large prospective 
trials showed that niacin did not improve prevention or 
reduce mortality.19,20 Although the original clinical trials 
were presumed to show clinical effectiveness, most were 
inadequately powered and relied on surrogate measures 
that had not been formally validated. Very few reported 
information on cardiovascular outcomes, and even fewer 
were designed to detect changes in these clinical outcomes.21 
Ultimately, the CEA published in Appendix C relied on 
data that were poor quality and its recommendations were 
invalidated when better outcome data became available. Since 
CEAs require synthesis of estimates from various sources, it is 
important that modelers communicate their assumptions and 
their reasons for selecting certain data sources over others. 
Justification for model inputs and parameters is integral to 
model transparency, especially when data is confidential or 
otherwise not publicly available. If the authors were required 
to publish technical documentation detailing the assumed 
relationship between lipid levels and cardiovascular risk, 
perhaps a reviewer or reader would have questioned their 
decision to use an unvalidated surrogate endpoint. 
It is possible to build accurate and useful economic 
models without relying solely on clinical data. Indirect and 
unintended outcome measures from more pragmatic settings 
and registries that take into account patient heterogeneity 
and real-life experiences should also be considered to answer 
a HTA question.22 Real-world evidence (RWE) is used by 
several HTA bodies to confirm or supplement findings 
from clinical trials,23 and in certain cases could be used to 
demonstrate treatment effects when clinical trials are not 
feasible or unethical, or when there is significant unmet 
need. Advanced statistical and data science techniques such 
as Deep IV, a deep neural net machine learning algorithm 
for counterfactual prediction,24 and E-value analysis of 
unmeasured confounding25 help address bias in observational 
data and permit causal inferences using RWE. RWE has 
utility in each stage of product lifecycles, from development to 
market access and post-launch.22 Of the assessments reviewed 
by Grutters et al, 23 were constructed without clinical data 
in early stages of development, all of which led to further 
development, research, or both.1 As with clinical trial data, 
transparency in analyses of RWE would further strengthen 
HTA insights gained. 
Despite agreement on the importance of transparency in 
health economic modeling, there is no definitive method 
for assessing transparency. However, all major guidelines 
emphasize reproducibility in their recommendations. Some 
argue that replication studies can effectively demonstrate 
how transparently a model is reported, identify potential 
calculation errors and inform future reporting practices.26 
The most recent paper to discuss the concept of a successful 
replication reported on the 8th Mt. Hood Diabetes Challenge 
Network: Economics, Simulation Modelling and Diabetes 
Competition,27 at which researchers compare their health 
economic diabetes models in terms of their structure and 
performance through coordinated tests in which they 
are asked to reproduce a real-world result.28 Through the 
competition’s process, the researchers present their models 
in greater detail than typically provided in publications, and 
may compare data sources, underlying code, and calibration 
techniques. In the competition, the replication challenge was 
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used to indicate reporting transparency, and their proposed 
definition of replication success was described in terms 
of model transparency.27 Recently, the Mt. Hood Diabetes 
Challenge Network has developed formal guidelines and a 
checklist, published in Value in Health,27 to further improve 
transparency in reporting of input data and other information 
underlying model-based analyses for diabetes. 
In 2018, Shao et al participated the 9th Mt. Hood Challenge 
to demonstrate that their BRAVO microsimulation model of 
diabetes costs and outcomes,29 based on the publicly available 
ACCORD patient-level clinical trial data, performs much 
better on many, if not all, dimensions than other advanced 
diabetes models, all of which are based on the much older 
UKPDS data.30 In development of BRAVO, Shao et al devised 
a novel approach to estimate regional multipliers for diabetes 
models that are constructed using data from a single region, 
thereby improving prediction accuracy by reducing systematic 
bias and increasing explanation power.31 Typical methods for 
external validation comparing model predictions to outcomes 
from single-region clinical trials may only weakly assess Shao 
et al’s new approach. However, the Mt. Hood Challenge 
provided Shao et al a unique opportunity to validate their 
approach against that of their competitors, permitting them 
to thoroughly identify inconsistencies and determine their 
source, whether it be the data and/or model calibration.
Of course, conferences and competitions are not feasible 
for every systematic evaluation of HTAs. Model registration 
combined with a linked database of model-based economic 
evaluations has been proposed as a solution, whereby 
registered models and their accompanying technical and 
nontechnical documentation are sourced into a single 
publicly-available repository, ideally in a standardized format 
to ensure consistent and complete representation of features, 
code, data sources, results, validation exercises, and policy 
recommendations.32 Such a registry would aid researchers 
and decision-makers who are interested in comparing HTAs, 
their characteristics, and their relative performance and 
accuracy to examine and factor all available information 
into their evaluations. A registry would additionally facilitate 
collaboration between researchers while avoiding duplicating 
efforts to answer certain policy questions or validate existing 
models. ISPOR has already convened a Special Interest Group 
that is currently undertaking development of such an open-
source platform. In the last year, it has developed tools for 
the ISPOR website, Short Courses, manuscripts in draft for 
scientific journals, webinars, and presentations in order to 
promote open-source modeling. The Mount Hood Diabetes 
Challenge Network has also created an initial registry for 
diabetes models in response to recent calls for a registry of 
economic models, located on their website.33 While their 
registry does not require model code to be made available 
and is currently limited to non-technical documentation, 
with outside links to technical descriptions and published 
reports, the Network is currently establishing a structured 
form to house technical and non-technical documentation 
of contributing models.32 When a repository is ultimately 
created, modelers will not have to reinvent the wheel for every 
new drug launched or new treatment pathway. 
Grutters et al were disinclined to report the point estimate 
results of assessments in terms of expected costs, effects, or 
cost-effectiveness without proper explanation of the context of 
analysis and quality of underlying evidence. An open-source 
repository of models would make this information publicly 
available through accompanying documentation, permitting 
Grutters et al to critically examine these results in their study. 
Assuming that technical documentation would also include 
probabilistic and scenario analyses beyond that typically 
reported in published manuscripts, Grutters et al could have 
additionally commented on existing uncertainty surrounding 
care. Although Grutters et al have presented many important 
insights, they caution that their recommendations cannot be 
interpreted independently as they are strongly related to both 
the value proposition and positioning of products. If a model 
repository were available, Grutters et al could have compared 
their included HTAs to those performed for competitor 
products at various stages of development, supplementing 
their sample so that it no longer represents only those 
innovations for which an early health economic modeling 
study was commissioned, thereby further informing value, 
positioning, and commercial viability. These more open and 
transparent approaches will have substantial implications for 
model accuracy, reliability, and validity, improving trust and 
acceptance by healthcare decision-makers. As Grutters et al 
aimed to demonstrate, evaluating the real-world performance 
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